EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions

Jerlon Chiu, Judd Fastenberg, Charles Tong iD, Brianne Navetta-Modrov, Sonya Marcus iD

Laryngoscope Investigative Otolaryngology · 2025-10 · 10 (5)

DOI: 10.1002/lio2.70282 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Laryngoscope Investigative Otolaryngology, online erschienen am 18.10.2025. Verfasst von Jerlon Chiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Otolaryngology-Head & Neck Surgery Stony Brook University Stony Brook New York USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2 inflammatory disease that often persists despite medical and surgical treatments. Recently, biologic therapies targeting key cytokines—interleukin (IL)‐4, IL‐5, IL‐13—and immunoglobulin E (IgE) have transformed management options for patients with severe or recurrent disease. Dupilumab, omalizumab, and mepolizumab are FDA‐approved biologics proven to reduce polyp size, improve symptoms, and enhance quality of life in clinical trials. Guidelines now endorse the use of biologics in select patients with evidence of type 2 inflammation and inadequate control after standard treatments. However, challenges remain, including high costs, uncertain treatment duration, lack of direct comparisons, and absence of validated biomarkers to guide selection. Additionally, the optimal role of biologics relative to endoscopic sinus surgery is not yet clear. Emerging therapies—including long‐acting anti–IL‐5 agents and new targets like TSLP and IL‐33—may further broaden options. Research is also needed for patients with non‐type two inflammation who respond poorly to current treatments. Ultimately, personalized approaches based on disease phenotype and biomarkers are crucial to optimizing outcomes. This review summarizes current evidence and future directions for biologic use in CRSwNP, focusing on efficacy, patient selection, surgery integration, and precision medicine opportunities.

Schlagwörter

Stichwörter der Autor:innen

biologicschronic rhinosinusitisnasal polyposis

Autor:innen und Institutionen

  • Division of Otolaryngology-Head & Neck Surgery Stony Brook University Stony Brook New York USA.
  • Northwell New Hyde Park New York USA.
  • Department of Otolaryngology-Head and Neck Surgery Zucker School of Medicine at Hofstra/Northwell Hempstead New York USA.
  • Department of Medicine Stony Brook University Stony Brook New York USA.

ORCID-Profile: Charles Tong, Sonya Marcus

Zitieren

APA

Chiu, J., Fastenberg, J., Tong, C., Navetta-Modrov, B., & Marcus, S. (2025). Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions. Laryngoscope Investigative Otolaryngology, 10(5). https://doi.org/10.1002/lio2.70282

Vancouver

Chiu J, Fastenberg J, Tong C, Navetta-Modrov B, Marcus S. Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions. Laryngoscope Investigative Otolaryngology. 2025;10(5). doi:10.1002/lio2.70282

BibTeX
@article{Chiu2025,
  author = {Chiu, Jerlon and Fastenberg, Judd and Tong, Charles and Navetta-Modrov, Brianne and Marcus, Sonya},
  title = {Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future Directions},
  journal = {Laryngoscope Investigative Otolaryngology},
  year = {2025},
  volume = {10},
  number = {5},
  doi = {10.1002/lio2.70282}
}
Kostenlos starten →